Alaunos Therapeutics (TCRT) Short term Debt (2021 - 2023)

Alaunos Therapeutics has reported Short term Debt for 3 years, with the latest figure at $11.0 million in Q1 2023.

• For the quarter ending Q1 2023, Short term Debt fell 21.48% year-over-year to $11.0 million; the trailing twelve-month figure through Mar 2023 stood at $11.0 million (down 21.48% YoY), and the FY2022 full-year result was $16.8 million, up 113.08% from the prior year.
• Short term Debt for Q1 2023 stood at $11.0 million, down from $16.8 million in the prior quarter.
• The five-year high for Short term Debt was $22.7 million in Q3 2022, with the low at $7.9 million in Q4 2021.
• Historically, Short term Debt has averaged $14.9 million across 3 years, with a median of $14.0 million in 2022.
• Annual changes were most pronounced in 2022 — Short term Debt soared 113.08% — and 2023, when it declined 21.48%.
• Alaunos Therapeutics' Short term Debt stood at $7.9 million in 2021, then soared by 113.08% to $16.8 million in 2022, then plunged by 34.46% to $11.0 million in 2023.
• The last three Short term Debt figures came in at $11.0 million (Q1 2023), $16.8 million (Q4 2022), and $22.7 million (Q3 2022), per Business Quant data.